NRX Pharmaceuticals, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
NRX Pharmaceuticals, Inc. (NRXP) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$273.30 million for the 3-month period ending 2021-06-30, per its 10-Q filed 2022-08-15.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2022-08-15
- NRX Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2021-06-30 was -$273.30M, a 267288.40% decline year-over-year.
- NRX Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2020-06-30 was $102.29K.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month as first filed |
|---|---|---|---|---|
| 2021-06-30 | -$273.30M 10-Q · filed 2022-08-15 | -$16.01M 10-Q · filed 2021-08-16 | -$298.79M 10-Q · filed 2022-08-15 | -$41.50M 10-Q · filed 2021-08-16 |
| 2020-06-30 | $102.29K 10-Q/A · filed 2022-08-12 | -$1.49M 10-Q/A · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |